FY2025 · ended Sep 30, 2025 · Revenue $236,561, +0.0% YoY · Filed Dec 30, 2025
Regen Biopharma, Inc. (RGBP) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Sep 30, 2025, it reported revenue of $236,561 and a net loss of $1.3 million.
Revenue (TTM)
$236,560
-0.0% vs year-ago TTM
Net income
$-1.27M
-90.7% vs prior year
Operating cash flow (TTM)
$-445,249
-3.3% vs year-ago TTM
Free cash flow
—
EPS
$-0.05
+68.8% vs prior year
Dividend per share
None
Shares outstanding
108.05M
+401.3% vs prior year
Net cash
—
Operating margin
-339.8%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- RGBP (OTC), RGBPP (OTC)
- Fiscal year ends
- September 30
- Incorporated in
- NV
- Headquarters
- La Mesa, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1589150
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Sep 30, 2025 |
FY 2024 Sep 30, 2024 |
FY 2023 Sep 30, 2023 |
FY 2022 Sep 30, 2022 |
FY 2021 Sep 30, 2021 |
|---|---|---|---|---|---|
| Revenue | $236,561 | $236,560 | $126,560 | $125,517 | $61,194 |
| Operating income | -$338,540 | -$417,221 | -$686,950 | -$339,605 | -$200,771 |
| Net income | -$1.3M | -$668,255 | $1.2M | $2.4M | -$6.8M |
| Diluted EPS | -$0.05 | -$0.16 | $0.29 | — | — |
| Operating cash flow | -$383,591 | -$751,536 | -$173,917 | -$606,921 | -$1.1M |
| Total assets | $274,628 | $161,084 | $353,617 | $559,002 | — |
| Total liabilities | $6.6M | $5.4M | $5.5M | $8.6M | — |
| Stockholders' equity | -$6.3M | -$5.2M | -$5.1M | -$8.0M | — |
| Cash and investments | $69,555 | $716 | — | $51,204 | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement
|
Nov 2, 2026 | Oct 27, 2026 |
| 10-Q | Quarterly report | Aug 17, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement, Auditor change, Other events
|
Jul 15, 2026 | Jul 10, 2026 |
| 10-Q | Quarterly report | May 14, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Unregistered share sale
|
Mar 4, 2026 | Feb 4, 2026 |
| 10-Q | Quarterly report | Feb 13, 2026 | Dec 31, 2025 |
All 263 Regen Biopharma, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.